SequelSEC

INTERPACE BIOSCIENCES, INC. IDXG

Surgical & Medical Instruments & Apparatus · CIK 0001054102 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$36.14M
Fiscal year ended 2026-06-30
Operating income
$4.17M
Fiscal year ended 2026-06-30
Free cash flow
$4.10M
Fiscal year ended 2026-06-30

INTERPACE BIOSCIENCES, INC. (IDXG) reported revenue of $36.14M and net income of $24.45M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from INTERPACE BIOSCIENCES, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Surgical & Medical Instruments & Apparatus.

Income

INTERPACE BIOSCIENCES, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$36.14M
Cost of revenue$13.10M
Gross profit$23.04M
Operating income$4.17M
Net income$24.45M
Research & development$594.00K
Weighted-average diluted sharesUnavailable
Pretax income$4.00M
Income tax expense-$20.86M
Diluted EPSUnavailable
Selling, general & administrative$18.28M
General & administrative$9.70M
Selling & marketing$8.58M

Balance

INTERPACE BIOSCIENCES, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$2.69M
Total assets$34.55M
Current assets$10.97M
Total liabilities$11.30M
Current liabilities$4.95M
Total equity incl. NCI$23.24M
Temporary (mezzanine) equityUnavailable
Inventory$1.08M
Accounts receivable$6.31M
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$1.56M

Cash flow

INTERPACE BIOSCIENCES, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow$4.46M
Capital expenditures$353.00K
Investing cash flow-$353.00K
Financing cash flowUnavailable
Net change in cash$2.19M
Stock-based compensation$19.00K
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$474.00K

Derived

INTERPACE BIOSCIENCES, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow$4.10M
Gross margin63.7%
Operating margin11.5%
FCF margin11.4%
SBC / revenue0.1%
Current ratio2.22x
Revenue YoY growth-20.5%
Net margin67.6%
R&D / revenue1.6%
CapEx / revenue1.0%
Long-term debt / equityUnavailable
Effective tax rate-521.8%

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open IDXG in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-10View SEC filing
10-Q · Filed 2026-05-12View SEC filing
10-K · Filed 2026-03-30View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-Q · Filed 2025-08-07View SEC filing
10-Q · Filed 2025-05-08View SEC filing

Companies in the same industry

ADGM AEMD ALUR AMIX ANGO ANIK AORT APYX ARAY ATEC ATRC AURX

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.